title: [CLINICAL EFFECTS OF TREATMENT FOR MYCOBACTERIUM TUBERCULOSIS INFECTION IN PATIENTS AT A SPECIALIZED HOSPITAL IN 2011].
abstract: OBJECTIVE
  We analyzed the clinical effects of treatment for Mycobacterium tuberculosis infection for 1 year in our specialized hospital in 2011. Two hundred and ninety-six (296) patients were admitted and received treatment.
  
  
  RESULTS
  Two hundred and fifty-six patients (86.5%) were started on the standard treatment with 3 drugs (isoniazid [INH, rifampicin [RFP], and ethambutol [EB] or streptomycin [SM]) or 4 drugs (INH, RFP, EB or SM, and pyrazinamide [PZA]). One hundred and seventy-one patients (66.8%) continued receiving the standard treatment during the admission period. Of 160 cases who could continue 4 drugs, under 80 year-old patients were 127 cases (76.0%), but over 80 year-old patients were 33 cases (49.3%). The mean duration for negative conversion of sputum culture was 40.6 days. Liver dysfunction due to 4 drugs (INH, RFP, EB, and PZA) was noted in 8.5% of patients. Eighteen of the 296 patients had multi-drug resistant tuberculosis (MDR-TB). Each MDR-TB patient received individualized treatment. Moreover, 7 of the MDR-TB cases were treated surgically.
  
  
  CONCLUSIONS
  Treatment of TB had taken long time, and some patients could not continue the treatment owing to the adverse effects of drugs. Hence, it is important to monitor adverse effects of drugs in each patient.
authors.forename: Masao
authors.initials: M
authors.lastname: Okumura
authors.forename: Yuka
authors.initials: Y
authors.lastname: Sasaki
authors.forename: Takashi
authors.initials: T
authors.lastname: Yoshiyama
authors.forename: Shuichi
authors.initials: S
authors.lastname: Matsuda
authors.forename: Takeshi
authors.initials: T
authors.lastname: Osawa
authors.forename: Kozo
authors.initials: K
authors.lastname: Morimoto
authors.forename: Hideki
authors.initials: H
authors.lastname: Yanai
authors.forename: Atsuyuki
authors.initials: A
authors.lastname: Kurasima
authors.forename: Hideo
authors.initials: H
authors.lastname: Ogata
authors.forename: Hajime
authors.initials: H
authors.lastname: Gotoh
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D002648:Child; D024881:Drug Resistance, Bacterial; D024901:Drug Resistance, Multiple, Bacterial; D004977:Ethambutol; D005260:Female; D006782:Hospitals, Special / Q000706:statistics & numerical data*; D006801:Humans; D007538:Isoniazid; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D011718:Pyrazinamide; D012189:Retrospective Studies; D012293:Rifampin; D013307:Streptomycin; D013997:Time Factors; D016896:Treatment Outcome; D014376:Tuberculosis / Q000188:drug therapy* / Q000382:microbiology; D055815:Young Adult
chemical_list: D000995:Antitubercular Agents; D011718:Pyrazinamide; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin